Biotech stocks notched a record on Tuesday—just not the kind that investors necessarily wanted to witness. Eight biotech companies announced plans to issue shares via secondary offerings. This marked a new single-day record for deals even if not for total dollars sought, according to Dealogic. Combined, the companies are set to raise proceeds of nearly $1.2 billion
…investor reaction to the spate of deals was sharply negative: All eight companies traded lower early Wednesday [before the discounted offering prices were even announced]…
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”